Transfusion strategy in hematological intensive care unit: Study protocol for a randomized controlled trial

Trials

Volumn 16, Issue 1, 2015, Pages

  Chantepie, Sylvain P ^a   Mear, Jean Baptiste ^a   Guittet, Lydia ^a,b   Dervaux, Benoît ^c   Marolleau, Jean Pierre ^d   Jardin, Fabrice ^e   Dutheil, Jean Jacques ^a   Parienti, Jean Jacques ^a   Vilque, Jean Pierre ^a   Reman, Oumedaly ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b Axe 2: 'Biology and Innovative Therapeutics for Locally Aggressive Cancers'   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e Centre Becquerel   (France)

Author keywords

Acute leukemia; Blood transfusion; Bone marrow transplantation

Indexed keywords

HEMOGLOBIN; TROPONIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ACUTE LEUKEMIA; ADULT; ARTICLE; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CONTROLLED STUDY; DEATH; ERYTHROCYTE CONCENTRATE; HEALTH CARE COST; HEART FAILURE; HEMATOLOGICAL PROCEDURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TRANSIENT ISCHEMIC ATTACK; ADVERSE EFFECTS; ALLOGRAFT; AUTOGRAFT; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; ERYTHROCYTE TRANSFUSION; FRANCE; HEMATOLOGY; INDUCTION CHEMOTHERAPY; LEUKEMIA; METABOLISM; PATIENT SELECTION; PREDICTIVE VALUE; PROCEDURES; RISK FACTOR; SAMPLE SIZE; TIME FACTOR; TREATMENT OUTCOME;

ALLOGRAFTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOGRAFTS; BIOMARKERS; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; ERYTHROCYTE TRANSFUSION; FRANCE; HEALTH CARE COSTS; HEMATOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINS; HUMANS; INDUCTION CHEMOTHERAPY; INTENSIVE CARE UNITS; LEUKEMIA; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SAMPLE SIZE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84947910806     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-015-1057-7     Document Type: Article

References (12)

1. Holst LB, Petersen MW, Haase N, Perner A, Wetterslev J. Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis. BMJ. 2015;350:h1354.
2. Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2012;4:CD002042.
3. Carless PA, Henry DA, Carson JL, Hebert PP, McClelland B, Ker K. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2010:CD002042. doi: 10.1002/14651858.CD002042.pub2.
4. Carson JL, Carless PA, Hebert PC. Outcomes using lower vs higher hemoglobin thresholds for red blood cell transfusion. JAMA. 2013;309:83-4.
5. Robitaille N, Lacroix J, Alexandrov L, Clayton L, Cortier M, Schultz KR, et al. Excess of veno-occlusive disease in a randomized clinical trial on a higher trigger for red blood cell transfusion after bone marrow transplantation: a Canadian blood and marrow transplant group trial. Biol Blood Marrow Transplant. 2013;19:468-73.
6. Berger MD, Gerber B, Arn K, Senn O, Schanz U, Stussi G. Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation. Haematologica. 2012;97:116-22.
7. Mear J-B, Chantepie S, Gac A-C, Bazin A, Reman O. A restrictive strategy reduces the number of transfused packed red blood cells in allograft recipients. Blood. 2014;124:5106-6. Abstract.
8. Transfusion De Globules Rouges Homologues: Produits, Indications, Alternatives. Méthode Recommandations pour la pratique clinique; http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-02/transfusion_de_globules_rouges_homologues_-_produits_indications_alternatives_-_recommandations.pdf: novembre 2014.
9. Guide AM. Choices in methods for economic evaluation. Public Health Assessment Haute Autorité de Santé. 2012.
10. Chevalier J, de Pouvourville G. Valuing EQ-5D using time trade-off in France. Eur J Health Econ. 2013;14:57-66.
11. Webert KE, Cook RJ, Couban S, Carruthers J, Lee K-A, Blajchman MA, et al. A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion. 2008;48:81-91.
12. Jansen AJG, Caljouw MAA, Hop WCJ, van Rhenen DJ, Schipperus MR. Feasibility of a restrictive red-cell transfusion policy for patients treated with intensive chemotherapy for acute myeloid leukaemia. Transfus Med. 2004;14:33-8.